Mayo Clinic Health Manager
Get free personalized health guidance for you and your family.
Get Started
close window
Housecall Archives
About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
close window
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Risk factors
By Mayo Clinic staffAlthough the exact cause of IgA nephropathy is unknown, some factors may increase your risk of developing this condition:
- Age. IgA nephropathy can affect people of all ages, including children, but it's most likely to strike people in their 20s and 30s.
- Your sex. In the West, IgA nephropathy affects about twice as many men as it does women.
- Ethnicity. IgA nephropathy is more common in Caucasians and Asians than it is in blacks.
- Family history. In some cases, IgA nephropathy appears to run in families, indicating that genetic factors may contribute to the disease.
References
- IgA nephropathy. National Kidney and Urologic Diseases Information Clearinghouse. http://kidney.niddk.nih.gov/kudiseases/pubs/iganephropathy. Accessed Aug. 31, 2008.
- Strippoli GF, et al. Evidence-based survey of therapeutic options for IgA nephropathy: Assessment and criticism. American Journal of Kidney Disease. 2003;41(6):1129-1139.
- Glomerulonephritis. MayoClinic.com. http://www.mayoclinic.com/health/glomerulonephritis/DS00503. Accessed Aug. 31, 2008.
- Donadio JV, et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Journal of the American Society of Nephrology. 1999;10(8):1772-1777.
- Donadio JV, et al. IgA nephropathy. The New England Journal of Medicine. 2002;738-748.
- Coppo R, et al. IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. Journal of the American Society of Nephrology. 2007;18(6):1880-1888.
- Barratt J, et al. Causes and diagnosis of IgA nephropathy. http://www.uptodate.com/home/index/html. Accessed Aug. 31, 2008.
- Cattran DC, et al. Treatment and prognosis of IgA nephropathy. http://www.uptodate.com/home/index.html. Accessed Aug. 31, 2008.
- Coppo R, et al. Factors predicting progression of IgA nephropathies. Journal of Nephrology. 2005;18(5):503-512.
- Gharavi AG, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nature Genetics. 2000;26:354-357.
